免疫检查点抑制剂治疗晚期肝细胞癌患者研究进展  

Application of immune checkpoint inhibitors in treatment of patients with advanced hepatocellular carcinoma

作　　者：陈鹏[1] 刘欢(综述)[1] 徐亮(审校)[1] Chen Peng;Liu Huan;Xu Liang(Department of Chronic Liver Diseases,Second People’s Hospital,Tianjin 300192,China)

机构地区：[1]天津市第二人民医院慢性肝病科,300192

出　　处：《实用肝脏病杂志》2023年第3期453-456,共4页Journal of Practical Hepatology

基　　金：中国肝炎防治基金会资助项目(编号:TQGB20210175)。

摘　　要：免疫检查点抑制剂是一种癌症免疫治疗药物,通过改善肿瘤周围免疫微环境而达到抗肿瘤目的。肝细胞癌是最常见的原发性肝癌类型,疾病晚期的治疗效果差。免疫检查点抑制剂治疗晚期肝细胞癌具有一定的疗效。本文对免疫检查点抑制剂在晚期肝细胞癌应用的作用机制、治疗进展和不良事件作一综述。Immune checkpoint inhibitor is a kind of cancer immunotherapy agents,which has anti-tumor activities by improving immune microenvironment around the tumors.The hepatocellular carcinoma(HCC)is the most common primary liver cancer,and the treatment efficacy of advanced disease is poor.The immune checkpoint inhibitors have a certain effects on advanced HCC.In this article,we will review the mechanism,treatment and adverse events of immune checkpoint inhibitors in treating patients with advanced HCC.

关 键 词：肝细胞癌 免疫检查点抑制剂 治疗 不良事件 

分 类 号：R735.7[医药卫生—肿瘤]